SK Bioscience is advancing its corporate operational system and implementing an integrated management framework that seamlessly connects all stages from development to production.
On Wednesday, the company announced the creation of a new Chief Operating Officer (COO) position to oversee the entire value chain. Park Jin-seon, former head of marketing and business development (BD), has been appointed to this role.
To bolster its global manufacturing and quality competitiveness, SK Bioscience has recruited Lee Sang-yoon as the head of the L House factory and Bio Research Division. Lee previously led the Technical Support Center at Samsung Biologics. The company has also brought on Lee Beom-han, former quality assurance (QA) group leader at Hanmi Pharmaceutical, as the new head of Quality Excellence (QE).
These strategic appointments aim to establish an integrated control tower, ensuring smooth coordination of vaccine development, commercial production, and global partnerships within a unified system.
SK Bioscience recognizes the critical need for operational optimization as its next-generation 21-valent pneumococcal vaccine, co-developed with Sanofi, progresses through global Phase 3 clinical trials and new vaccine projects enter full development stages.
With the move to the Songdo Global Research and Development (R&D) Center, the company plans to significantly upgrade its research and process infrastructure. This transition will enhance management efficiency and strengthen collaborations with partners, paving the way for global market expansion.
Newly appointed COO Park, a Seoul National University pharmacy graduate, brings extensive global business expertise to the role. His experience spans overseas business development, BD leadership, and marketing & business development management. Park will leverage his comprehensive knowledge to enhance the market competitiveness of in-house products and oversee the commercialization of new pipelines.
Lee, who will also head the L House factory in Andong, is a process innovation expert with a track record of leading large-scale commercial production and technology transfers at Samsung Biologics and Celltrion. He aims to design optimal manufacturing processes that consider global supply needs from the early research stages, bridging the L House operations with the Bio Research Division.
Lee Beom-han, the new QE head responsible for global quality management, brings over two decades of quality assurance experience. He has successfully guided product approvals from global regulatory bodies, including the U.S. Food and Drug Administration (FDA). Lee Beom-han will focus on establishing a world-class quality management system aligned with the global expansion of key pipelines.
Through this strategic reorganization, SK Bioscience aims to position itself as a leading player in the global vaccine and biotech market.
